KDR and gastric cancer: In prior clinical reports, nivolumab (ATTRACTION 2 study), pembrolizumab (KEYNOTE-059 study, cohort 1), trifluridine/tipiracil (TAGS study) and apatinib (a small-molecule VEGFR inhibitor developed mainly in China), which had been administered in the third-line setting for GC, achieved ORRs of 11.2%, 13.3%, 4% and 1.7%, respectively19–22.